List Biological Laboratories
List Labs is a pioneering CDMO specializing in microbiology and bacterial products, with over 45 years of experience. They support research, vaccine development, and transformative therapies, including Live Biotherapeutic Products (LBPs). The company emphasizes quality, innovation, and collaboration, offering end-to-end solutions from early-stage development to commercial manufacturing. Their expertise spans aerobic, anaerobic, and spore-forming bacteria, with state-of-the-art facilities designed for GMP compliance and containment. List Labs is committed to advancing microbiome research and supporting clients through all phases of product development, including scale-up, analytical testing, regulatory support, and commercial manufacturing. They have a history of producing the first LBP for clinical trials and continue to expand their capacity with new facilities and partnerships, aiming to be a global leader in microbiome CDMO services.
Industries
Nr. of Employees
small (1-50)
List Biological Laboratories
Campbell, California, United States, North America
Patents
Products
Recombinant protein substrate (lyophilized)
Recombinant fusion protein substrate for proteolytic cleavage assays and toxin activity detection, provided as a lyophilized powder with Certificate of Analysis and defined storage conditions.
Catalog of bacterial research reagents
Extensive catalog of reagents including bacterial toxins, toxoids, lipopolysaccharides (LPS), peptide substrates, carrier proteins, adjuvants and antibodies; selected items available as GMP-grade on request.
GMP-grade lipopolysaccharides (LPS)
LPS products manufactured and released under GMP controls for regulated research, assay controls and clinical workflows.
Liquid formulation of toxin (research use)
High-activity liquid formulation of a bacterial toxin provided for research and assay development with improved activity and refrigerated stability.
Recombinant protein substrate (lyophilized)
Recombinant fusion protein substrate for proteolytic cleavage assays and toxin activity detection, provided as a lyophilized powder with Certificate of Analysis and defined storage conditions.
Catalog of bacterial research reagents
Extensive catalog of reagents including bacterial toxins, toxoids, lipopolysaccharides (LPS), peptide substrates, carrier proteins, adjuvants and antibodies; selected items available as GMP-grade on request.
GMP-grade lipopolysaccharides (LPS)
LPS products manufactured and released under GMP controls for regulated research, assay controls and clinical workflows.
Liquid formulation of toxin (research use)
High-activity liquid formulation of a bacterial toxin provided for research and assay development with improved activity and refrigerated stability.
Services
End-to-end services from early-stage process development through cGMP clinical manufacturing and supply for live bacterial therapeutics, including strain-specific development and multi-format fill-finish.
cGMP-compliant production and release of clinical material for early-phase trials with lot-level release testing, COA documentation and coordination of shipping/export controls.
Feasibility assessments, pilot runs and process optimization using scaled-down models and staged scale-up to develop robust, scalable upstream and downstream processes for bacterial products.
Media formulation development to replace animal-derived components for BSE/TSE-free production, addressing growth rate, cell density, phenotype, potency and viability impacts.
Optimization of harvest timing, harvest processes, formulation, lyophilization and filling to maximize viable organism yield and stability through manufacturing and distribution.
Development and validation of bioburden assays, in-process and final QC tests tailored to live organisms, stability programs and lot-release analytics.
End-to-end services from early-stage process development through cGMP clinical manufacturing and supply for live bacterial therapeutics, including strain-specific development and multi-format fill-finish.
cGMP-compliant production and release of clinical material for early-phase trials with lot-level release testing, COA documentation and coordination of shipping/export controls.
Feasibility assessments, pilot runs and process optimization using scaled-down models and staged scale-up to develop robust, scalable upstream and downstream processes for bacterial products.
Media formulation development to replace animal-derived components for BSE/TSE-free production, addressing growth rate, cell density, phenotype, potency and viability impacts.
Optimization of harvest timing, harvest processes, formulation, lyophilization and filling to maximize viable organism yield and stability through manufacturing and distribution.
Development and validation of bioburden assays, in-process and final QC tests tailored to live organisms, stability programs and lot-release analytics.
Expertise Areas
- Live biotherapeutic product (LBP) development and clinical manufacturing
- Microbial process development and scale-up
- Fermentation and bioreactor cultivation (single-use and stainless-steel)
- Downstream processing and purification for bacterial-derived products
Key Technologies
- cGMP manufacturing systems and segregated ISO cleanrooms
- Pilot and commercial-scale fermentation including anaerobic processes
- Single-use and stainless-steel bioreactor platforms
- Scale-down bioreactor modeling and staged scale-up protocols
News & Updates
List Labs will exhibit at the ASM Biothreats Conference in Baltimore, Maryland, showcasing products related to biothreat reduction.
List Labs will exhibit at the ASM Biothreats Conference in Baltimore, Maryland, showcasing products related to biothreat reduction.